Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy

Mary E. Platek, Mary E. Reid, Gregory E. Wilding, Wainwright Jaggernauth, Nestor R. Rigual, Wesley L. Hicks, Saurin R. Popat, Graham W. Warren, Maureen Sullivan, Wade L. Thorstad, Mohamed K. Khan, Thom R. Loree, Anurag K. Singh

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Background This study was carried out to determine if markers of nutritional status predict for locoregional failure following intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN). Methods We performed a retrospective chart review of 78 patients with SCCHN who received definitive CCRT. We compared patient factors, tumor characteristics, and nutritional status indicators between patients with and without locoregional failure. Results Fifteen of 78 patients (19%) experienced locoregional failure. Median follow-up for live patients was 38 months. On univariate analysis, pretreatment percentage of ideal body weight (%IBW) (p <.01), pretreatment hemoglobin (p =.04), and treatment duration (p <.01) were significant predictors of failure. On multivariate analysis, pretreatment %IBW (p =.04) and treatment time (p <.01) remained statistically significant. Conclusions Although treatment time is an accepted risk factor for failure, differences in outcome for patients with head and neck cancer undergoing definitive CCRT based on pretreatment %IBW should be examined further.

Original languageEnglish
Pages (from-to)1561-1568
Number of pages8
JournalHead and Neck
Volume33
Issue number11
DOIs
StatePublished - Nov 2011

Keywords

  • concurrent chemoradiation therapy
  • ideal body weight
  • nutrition
  • percutaneous endoscopic gastrostomy tube
  • squamous cell carcinoma of the head and neck

Fingerprint

Dive into the research topics of 'Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy'. Together they form a unique fingerprint.

Cite this